Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avichai Shimoni

Showing results (41-50 of 165) with videos related to

Pageof 17
Sort By:
Acta Haematologica|August 26, 2015
Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot StudyIvetta Danylesko, Rina Sareli, Nira Varda-Bloom, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 1, 2021
Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction ChemotherapyGal Sharvit, Gabriel Heering, Maya Zlotnik, et al.
Experimental Hematology|May 24, 2003
Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicityAvichai Shimoni, Bella Bielorai, Amos Toren, et al.
Cells|December 24, 2021
CMV Seropositive Status Increases Heparanase SNPs Regulatory Activity, Risk of Acute GVHD and Yield of CD34<sup>+</sup> Cell MobilizationOlga Ostrovsky, Katia Beider, Yan Morgulis, et al.
Annals of Hematology|January 6, 2022
ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapyNaama Keren-Froim, Gabriel Heering, Gal Sharvit, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 22, 2013
Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trialDror Mevorach, Tsila Zuckerman, Inna Reiner, et al.
Haematologica|December 7, 2022
Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantationYaara Yerushalmi, Noga Shem-Tov, Ivetta Danylesko, et al.
Acta Haematologica|June 8, 2021
Complete Remission with Incomplete Blood Count Recovery Is a Strong Predictor of Nonrelapse Mortality in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell TransplantationIvetta Danylesko, Jonathan Canaani, Avichai Shimoni, et al.
Current Research in Translational Medicine|December 29, 2019
Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemiaIvetta Danylesko, Guy Chowers, Roni Shouval, et al.
Hematological Oncology|January 14, 2012
Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVECMaya Koren-Michowitz, Yulia Volchek, Elizabeth Naparstek, et al.
Pageof 17

Showing results (41-50 of 165) with videos related to

Sort By:
Pageof 17
Acta Haematologica|August 26, 2015
Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot StudyIvetta Danylesko, Rina Sareli, Nira Varda-Bloom, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 1, 2021
Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction ChemotherapyGal Sharvit, Gabriel Heering, Maya Zlotnik, et al.
Experimental Hematology|May 24, 2003
Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicityAvichai Shimoni, Bella Bielorai, Amos Toren, et al.
Cells|December 24, 2021
CMV Seropositive Status Increases Heparanase SNPs Regulatory Activity, Risk of Acute GVHD and Yield of CD34<sup>+</sup> Cell MobilizationOlga Ostrovsky, Katia Beider, Yan Morgulis, et al.
Annals of Hematology|January 6, 2022
ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapyNaama Keren-Froim, Gabriel Heering, Gal Sharvit, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 22, 2013
Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trialDror Mevorach, Tsila Zuckerman, Inna Reiner, et al.
Haematologica|December 7, 2022
Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantationYaara Yerushalmi, Noga Shem-Tov, Ivetta Danylesko, et al.
Acta Haematologica|June 8, 2021
Complete Remission with Incomplete Blood Count Recovery Is a Strong Predictor of Nonrelapse Mortality in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell TransplantationIvetta Danylesko, Jonathan Canaani, Avichai Shimoni, et al.
Current Research in Translational Medicine|December 29, 2019
Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemiaIvetta Danylesko, Guy Chowers, Roni Shouval, et al.
Hematological Oncology|January 14, 2012
Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVECMaya Koren-Michowitz, Yulia Volchek, Elizabeth Naparstek, et al.
Pageof 17